Seattle Genetics is a biotechnology company whose foundation is based on rigorous research, scientific innovations, and drug development practices. The company has a passion for providing help to patients from its developed clinical and preclinical products. Seattle Genetics was founded in 1998 by Clay Siegall and has over the years showed its commitment towards developing cancer treatment options.
Clay Siegall co-founded the company and serves in the capacity of President, CEO, as well as Board Chairman. Siegall is a scientist, and one of his areas of focus include cancer therapies. He has been able to guide Seattle Genetics to its current position as a leader in developing antibody-based therapies for patients. In January 2013, he was appointed as a Board member to Mirna Therapeutics, a biotechnology company with its focus on microRNA therapeutics and cancer research.
Seattle Genetics has created the antibody-drug conjugate (ADC) technology, which significantly reduces the toxic effects associated with chemotherapy. It involves different ADC programs including SGN-CD19A and SGN-CD33A. The SGN-CD33A program is applied for patients with acute myeloid leukemia while the latter is for non-Hodgkin lymphoma patients.
The company has also developed a complementary technology known as the Sugar-engineered antibody (SEA). This technology can be used to increase the effectiveness of monoclonal antibodies and can be used for solid tumors. Seattle Genetics is traded on Nasdaq Stock Market. Its current headquarters is in Bothell Washington.
Siegall has a passion for unmet medical needs especially in the diagnosis and treatment of cancer. He has a doctorate in Genetics and a Bachelor in Zoology. His leadership has seen the company enter into several strategic licenses with different global companies including Addvie, Pfizer, Genentech (Roche), and GlaxoSmithKline. These licenses were for its ADC technology, which has generated over $300million for the company.
Before co-founding Seattle Genetics, Siegall held different positions at the National Institute of Health, the Pharmaceutical Research Institute (Bristol-Myers Squibb), and the National Cancer Institute. He has demonstrated his leadership at Seattle by helping the company secure over $675 million in funding from the public as well as private organizations.